Skip to main content

Kodiak Sciences Inc

For the period ended Mar 31, 2024. Filed May 15, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

KOD$108.06+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(in thousands)

Three Months Ended March 31,
20242023
Cash flows from operating activities
Net loss$(43,039)$(70,780)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation4,7033,810
Stock-based compensation18,40925,980
Net amortization (accretion) of premium (discount) on marketable securities—(518)
Settlement of derivative contracts144—
Amortization of operating lease right-of-use asset1,9431,846
Amortization of issuance costs—4
Changes in assets and liabilities:
Prepaid expenses and other current assets(1,791)2,326
Other assets15(12)
Accounts payable(11,123)(1,900)
Accrued and other current liabilities(5,586)(5,370)
Operating lease liability(3,275)(2,607)
Net cash provided by (used in) operating activities(39,600)(47,221)
Cash flows from investing activities
Purchase of property and equipment(22)(12,170)
Deposits on property and equipment—(77)
Purchase of marketable securities—(49,347)
Maturities of marketable securities—235,000
Settlement of derivative contracts(144)—
Net cash provided by (used in) investing activities(166)173,406
Cash flows from financing activities
Proceeds from issuance of common stock upon options exercise389
Principal payments of tenant improvement allowance payable—(12)
Net cash provided by (used in) financing activities38(3)
Net increase (decrease) in cash, cash equivalents and restricted cash(39,728)126,182
Cash, cash equivalents and restricted cash, at beginning of period291,831196,757
Cash, cash equivalents and restricted cash, at end of period$252,103$322,939
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets
Cash and cash equivalents$245,919$316,615
Restricted cash6,1846,324
Total cash, cash equivalents and restricted cash in consolidated balance sheets$252,103$322,939
Supplemental disclosures of non-cash investing and financing information:
Operating lease right-of-use asset obtained in exchange for operating lease liability$(49)$1,473
Purchase of property and equipment under accounts payable and accruals$—$28,795
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.